These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27800023)

  • 21. Emerging drugs for partial-onset epilepsy: a review of brivaracetam.
    Gao L; Li S
    Ther Clin Risk Manag; 2016; 12():719-34. PubMed ID: 27217762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy.
    Savastano E; Pulitano P; Faedda MT; Davì L; Vanacore N; Mecarelli O
    Cureus; 2021 May; 13(5):e15012. PubMed ID: 34131547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of brivaracetam and its potential in the treatment of epilepsy.
    Ferlazzo E; Russo E; Mumoli L; Sueri C; Gasparini S; Palleria C; Labate A; Gambardella A; De Sarro G; Aguglia U
    Neuropsychiatr Dis Treat; 2015; 11():2967-73. PubMed ID: 26664121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.
    Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C
    Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
    Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
    Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.
    Kappes JA; Hayes WJ; Strain JD; Farver DK
    J Clin Pharmacol; 2017 Jul; 57(7):811-817. PubMed ID: 28394442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential role of brivaracetam in pediatric epilepsy.
    Verrotti A; Grasso EA; Cacciatore M; Matricardi S; Striano P
    Acta Neurol Scand; 2021 Jan; 143(1):19-26. PubMed ID: 32966640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug characteristics derived from kinetic modeling: combined
    Naganawa M; Gallezot JD; Finnema SJ; Maguire RP; Mercier J; Nabulsi NB; Kervyn S; Henry S; Nicolas JM; Huang Y; Chen MK; Hannestad J; Klitgaard H; Stockis A; Carson RE
    EJNMMI Res; 2022 Nov; 12(1):71. PubMed ID: 36346513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on brivaracetam for the treatment of pediatric partial epilepsy.
    Tulli E; Di Cara G; Iapadre G; Striano P; Verrotti A
    Expert Opin Pharmacother; 2021 Aug; 22(11):1387-1395. PubMed ID: 33896317
    [No Abstract]   [Full Text] [Related]  

  • 34. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience.
    Steinhoff BJ; Staack AM
    Ther Adv Neurol Disord; 2019; 12():1756286419873518. PubMed ID: 31523280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Brivaracetam in the treatment of patients with epilepsy].
    Karlov VA; Vlasov PN; Zhidkova IA; Kissin MY; Lebedeva AV; Lipatova LV; Mkrtchyan VR; Mukhin KY; Rudakova IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):55-62. PubMed ID: 29213040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brivaracetam: new compound approved for the treatment of epilepsy.
    Zaccara G
    Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials.
    Ma J; Huang S; You C
    Epilepsy Res; 2015 Aug; 114():59-65. PubMed ID: 26088886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.